Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor

• US 20040132045A1
• Filed: 11/20/2003
• Published: 07/08/2004
• Est. Priority Date: 05/31/2001
• Status: Active Grant

• Current Assignee: MSD Kabushiki Kaisha (Merck & Co., Inc.)
• Original Assignee: Merck & Co., Inc.
• Inventors: Sano, Hideki, Tan, Carina
• Granted Patent: US 7,208,282 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/72 for hormones for neuromediators C07K14/70571
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: G01N 33/9406 Neurotransmitters

Abstract

The present invention identifies the presence of MCH-2R in the dog, ferret and rhesus monkey. MCH-2R is a G-protein coupled receptor that responds to MCH and is distinct from MCH-1R. MCH-2R polypeptide and nucleic acid sequences related to the dog, ferret, and rhesus monkey MCH-2R are described herein along with uses of such polypeptides and nucleic acids.

Claims

1. A purified polypeptide comprising an amino acid sequence selected from the groups consisting of:

SEQ ID NO;

9, SEQ ID NO;

10, and SEQ ID NO;

11.

2. The polypeptide of claim 1, wherein said polypeptide consists of an MCH-2R dog, ferret, or rhesus sequence comprising SEQ ID NO:

9.

3. The polypeptide of claim 1, wherein said polypeptide consists of an MCH-2R dog, ferret, or rhesus sequence comprising SEQ ID NO:

10.

4. The polypeptide of claim 1, wherein said polypeptide consists of an MCH-2R dog, ferret, or rhesus sequence comprising SEQ ID NO:

11.

5. The polypeptide of claim 1, wherein said polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, and SEQ ID NO;

3.

6. The polypeptide of claim 5, wherein said polypeptide consists of SEQ ID NO:

1.

7. The polypeptide of claim 5, wherein said polypeptide consists of SEQ ID NO:

2.

8. The polypeptide of claim 5, wherein said polypeptide consists of SEQ ID NO:

3.

9. A purified nucleic acid comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-8.

18. A recombinant nucleic acid comprising either (a) a nucleotide sequence encoding the amino acid sequence of any one of claims 1-8 or (b) the sequence of any one of claims 10-17.

19. The recombinant nucleic acid of claim 18, wherein said recombinant nucleic acid is an expression vector.

20. A recombinant cell comprising an expression vector encoding the amino acid sequence of any one of claim 1-8 functionally coupled to a promoter recognized by said cell.

21. A recombinant cell made by a process comprising the step of introducing into said cell the expression vector of claim 19.

22. A method of measuring the ability of a compound to affect MCH-2R activity comprising the steps of:

a) contacting a recombinant cell with said compound, wherein said recombinant cell comprises a recombinant nucleic acid expressing a functional MCH-2R that comprises the amino acid sequence of any one of claim 1-8; and

b) measuring MCH-2R activity.

23. The method of claim 22, wherein said method further comprises the use of an MCH-2R agonist.

24. A method of preparing a MCH-2R polypeptide comprising the step of growing the recombinant cell of claim 20 under conditions wherein said polypeptide is expressed from said expression vector.

10. A purified nucleic acid comprising a nucleotide sequence selected from the group consisting of:

SEQ ID NO;

12, SEQ ID NO;

13, SEQ ID NO;

14, SEQ ID NO;

15, the complement of SEQ ID NO;

12, the complement of SEQ ID NO;

13, the complement of SEQ ID NO;

14, and the complement of SEQ ID NO;

15.

11. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

12 or the complement thereof.

12. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

13 or the complement thereof.

13. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

14 or the complement thereof.

14. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

15 or the complement thereof.

15. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

5 or the complement thereof.

16. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

6 or the complement thereof.

17. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO:

7 or the complement thereof.

25. A method of evaluating the ability of an MCH-2R active compound to exert an in vivo effect comprising the steps of:

a) measuring the ability of said compound to affect MCH-2R activity;

b) administering said compound to a subject selected from the group consisting of;

a rhesus monkey, a dog, and a ferret; and

c) measuring the effect of said compound on said subject.

26. The method of claim 25, wherein said step (c) measures alterations in weight.

27. The method of claim 25, wherein said step (c) measures energy metabolism.

28. The method of claim 25, wherein said step (c) measures appetite.

29. The method of claim 25, wherein said step (c) measures sexual activity.

30. The method of any one of claim 25-29, wherein said subject is said rhesus monkey.

31. The method of any one of claims 25-29, wherein said subject is said dog.

32. The method of any one of claims 25-29, wherein said subject is said ferret.